Effects and efficacy of Elafibranor-Iqirvo

Elafibranor (Elafibranor-Iqirvo is a once-daily oral tablet indicated for the treatment of primary biliary cholangitis (PBC) in adults who have had an inadequate response to UDCA, in combination with ursodeoxycholic acid (UDCA), or alone in patients who cannot tolerate UDCA.

Iqirvo, also known as GFT505, is a pharmaceutical compound designed to target peroxisome proliferator-activated receptors (PPARs). More specifically, Iqirvo is a dual ligand for PPARα and PPARδ. PPARs are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily, which gathers numerous genes that are not only involved in different metabolic processes but also in cellular functions. Other members of this superfamily are steroid hormone receptors, vitamin D3 receptors, retinoic acid receptors (RARs and RXRs), and thyroid hormone receptors (THRs).

Iqirvo and its main active metabolite are peroxisome proliferator-activated receptor (PPAR) agonists and act by activating PPAR receptors, a family of receptors that play a major regulatory role in energy homeostasis and metabolic function. Iqirvo activates PPAR-alpha and PPAR-delta, blocking bile acid production, although its exact mode of action in patients with primary biliary cholangitis is unknown.

Iqirvo is not recommended for people with signs or symptoms of advanced liver disease (decompensated cirrhosis), including confusion; fluid in the stomach area (abdomen); black, tarry, or bloody stools; coughing or vomiting blood, or vomit that looks like "coffee grounds." When using Iqirvo, doctors and patients should closely monitor the patient's physical condition, detect any abnormal reactions in a timely manner and take appropriate measures. Understanding the mechanism of action and indications of drugs can help patients better understand the treatment process, improve treatment effects, and reduce potential risks.